Home / Companies / Preferred Pharmaceuticals, Inc.

Preferred Pharmaceuticals, Inc.

FDA Regulatory Profile

Preferred Pharmaceuticals, Inc. has 56 FDA recalls, 6 inspections, 0 510(k) clearances and 0 compliance actions on record.

Latest recall
D-0013-2027 · Class II · Sep 28, 2026
Latest inspection
May 27, 2025 · VAI

Reviewing Preferred Pharmaceuticals, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Preferred Pharmaceuticals, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls56Nov 8, 2026File dated Nov 3, 2026Current
510(k) clearances0Nov 8, 2026File dated Nov 2, 2026Current
Inspections6Nov 11, 2026Newest record Nov 5, 2026Current
Compliance actions0Nov 2, 2026Newest record Oct 29, 2026Current

Recent Recalls

NumberClassProductDate
D-0013-2027Class IILidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro…Sep 28, 2026
D-0443-2026Class IIArtificial Tears Lubricant Eye Drops (glycerin 0.2%, hypromellose 0.2%, polyethylene glycol 400 1%)…Mar 25, 2026
D-0239-2026Class IIOndansetron ODT Tablets, USP 4mg, 1x10 unit dose tablets, Mfg: Glenmark Pharmaceuticals Limited…Nov 17, 2025
D-0391-2025Class IIClindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark…Apr 18, 2025
D-0647-2024Class IIIbuprofen Tablets, USP 400mg, Generic for Motrin, Pkg Size: 30 tablets per bottle, Mfg: Dr. Reddy's…Aug 8, 2024
D-0505-2024Class IIDuloxetine Delayed-Release Cap USP 30mg, 30-count bottle, Rx only, Preferred Pharmaceutcals, Inc…May 10, 2024
D-0894-2023Class IITizanidine Hydrochloride Tablet 4mg, packaged in a) 20 count-bottles (NDC 68788-7781-2), b)30-count…Jun 26, 2023
D-0504-2023Class IIAlprazolam Tab, USP 0.25mg, (CIV), 30-count bottle, Rx Only, Preferred Pharmaceuticals, Inc…Mar 27, 2023
D-0505-2023Class IIAlprazolam Tab, USP 0.5mg, (CIV), packaged in: a) 30-count bottle (NDC 68788-7595-3), b) 60-count…Mar 27, 2023
D-0506-2023Class IIAlprazolam Tab, USP 1mg, (CIV), packaged in: a) 30-count bottle (NDC 68788-7596-3), b) 60-count…Mar 27, 2023
D-0512-2023Class IIAtorvastatin Calcium Tablets, USP, 20 mg, packaged in: a) 90-count bottle (NDC 68788-7631-9); b)…Mar 23, 2023
D-0511-2023Class IIAtorvastatin Calcium Tablets, USP, 10 mg, 90-count bottle, Rx only, Manufactured: Accord Healthcare…Mar 23, 2023
D-0523-2023Class IISimvastatin Tablets, USP, 80 mg, 90-count bottle, Rx only, Manufactured for: Accord Healthcare…Mar 23, 2023
D-0521-2023Class IIPravastatin Sodium Tablets, USP, 20 mg, 90-count bottle, Rx only, Manufactured for: Accord…Mar 23, 2023
D-0514-2023Class IIDoxazosin Tablets, USP, 2 mg, 100-count bottle, Rx only, Manufactured: Accord Healthcare, Inc…Mar 23, 2023
D-0516-2023Class IIFinasteride Tablets, USP, 5 mg, packaged in: a) 30-count bottles (NDC 68788-6976-3); b) 90-count…Mar 23, 2023
D-0517-2023Class IIGlimepiride Tablets, USP, 2 mg, 90-count bottle, Rx only, Manufactured: Accord Healthcare, Inc…Mar 23, 2023
D-0527-2023Class IIGlimepiride Tablets USP, 4 mg, 90-count bottle, Rx only, Manufactured: Accord Healthcare, Inc…Mar 23, 2023
D-0513-2023Class IIClopidogrel Tablets USP, 75 mg, 90-count bottles, Rx only, Manufactured: Accord Healthcare, Inc…Mar 23, 2023
D-0515-2023Class IIDoxazosin Tablets, USP, 4 mg, 100-count bottle, Rx only, Manufactured: Accord Healthcare, Inc…Mar 23, 2023

Recent FDA Inspections

DateSiteProductClassificationFEI
May 27, 2025Anaheim, CADrugsVoluntary Action Indicated (VAI)3004582966
Jan 14, 2020Anaheim, CADrugsVoluntary Action Indicated (VAI)3004582966
Jan 29, 2018Anaheim, CADrugsVoluntary Action Indicated (VAI)3004582966
Oct 29, 2015Anaheim, CADrugsVoluntary Action Indicated (VAI)3004582966
Dec 17, 2010Anaheim, CADrugsNo Action Indicated (NAI)3004582966
Dec 30, 2009Anaheim, CADrugsVoluntary Action Indicated (VAI)3004582966

NAI means no objectionable conditions or practices were found during the inspection. VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. OAI means regulatory and/or administrative actions are recommended.

FDA-Inspected Facilities

FacilityLocationInspectionsLatest
FEI 3004582966Anaheim, CA6May 27, 2025

FDA data resources

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.